

Clinical Study

Are Breast Cancer Molecular Classes Predictive of Survival in Patients with Long Follow-Up?

Danae Pracella,¹ Serena Bonin,¹ Renzo Barbazza,¹ Anna Sapino,² Isabella Castellano,² Sandro Sulfaro,³ and Giorgio Stanta¹

¹ Department of Medical Sciences, Cattinara Hospital, Strada di Fiume 447, 34149 Trieste, Italy

² Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, 10126 Turin, Italy

³ Department of Laboratory Medicine, S.C. Pathology, Santa Maria degli Angeli Hospital, 33170 Pordenone, Italy

Correspondence should be addressed to Giorgio Stanta; stanta@icgeb.org

Received 19 June 2013; Accepted 25 September 2013

Academic Editor: Gunter Haroske

Copyright © 2013 Danae Pracella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this study we investigate the clinical outcomes of 305 breast cancer (BC) patients, aged 55 years or younger, with long follow-up and according to intrinsic subtypes. The cohort included 151 lymph node negative (LN⁻) and 154 lymph node positive (LN⁺) patients. Luminal A tumors were mainly LN⁻, well differentiated, and of stage I; among them AR was an indicator of good prognosis. Luminal B and HER2 positive nonluminal cancers showed higher tumor grade and nodal metastases as well as higher proliferation status and stage. Among luminal tumors, those PR positive and vimentin negative showed a longer survival. HER2-positive nonluminal and TN patients showed a poorer outcome, with BC-specific death mostly occurring within 5 and 10 years. Only luminal tumor patients underwent BC death over 10 years. When patients were divided in to LN⁻ and LN⁺ no differences in survival were observed in the luminal subgroups. LN⁻ patients have good survival even after 20 years of follow-up (about 75%), while for LN⁺ patients survival at 20 years (around 40%) was comparable to HER2-positive nonluminal and TN groups. In conclusion, in our experience ER-positive breast tumors are better divided by classical clinical stage than molecular classification, and they need longer clinical follow-up especially in cases with lymph node involvement.

1. Introduction

Breast carcinoma (BC) encompasses a heterogeneous group of tumors with great variability both at the molecular and at the morphological levels. Clinical outcome is also variable, some tumors are completely cured and others can recur even after more than 10 years from surgical treatment. Gene expression profiling through microarray technology has been designed to improve molecular taxonomy as a tool for supporting clinical management of patients [1–3]. According to molecular classification, BCs were grouped into at least four “intrinsic” subtypes: two ER-positive luminal-like subtypes and two ER-negative subtypes, HER2 overexpressing (HER2 positive nonluminal) and triple negative (TN). These intrinsic subtypes showed different prognosis and outcome [3, 4]. Luminal tumors, divided into A and B subtypes, include more than two-thirds of all BCs [5], while HER2 positive

nonluminal and triple negative (TN) make up, respectively, 15–20% and 10–15% of breast tumors [6]. However, due to the limitation of microarray-based molecular classification in clinical practice, immunohistochemical (IHC) classification by the analysis of estrogen receptor (ER), progesteron receptor (PR), human epidermal growth factor receptor-2 (HER2), and Ki67 (with a cutoff of 14%) has been proposed and has been shown to correlate with gene expression profiling data [6–11]. Furthermore, the St. Gallen consensus 2011 has strongly supported the clinicopathological determination of ER, PR, HER2, and Ki-67 as useful for defining subtypes, as well as providing treatment recommendations for BC intrinsic subtypes [7].

In normal breast tissue, luminal epithelial cells of ducts and lobules are characterized by the expression of low molecular weight cytokeratin CK8, CK18, CK19, and CK7. The outer layer includes more heterogeneous cells that express

high molecular weight cytokeratin, such as CK5/6 and CK14, as well as nonepithelial cell markers such as vimentin, alpha smooth muscle actin, but they do not express ER and PR [12]. During the cells cancer transformation process, the CK expression profile is often retained [13]. Basal-like tumors are considered as those expressing at least one marker typical of myoepithelial/basal cells [12], and for this reason cytokeratins can be used to confirm the molecular class of the tumor. Nevertheless, molecular classification is still a working model since a consensus on the definition of subtypes and on standardization of methodologies has not yet been completely reached [14, 15].

The present study was carried out on a cohort of patients under the age of 55 years (associated with a long follow-up period) and aimed to

- (i) classify BC in intrinsic subtypes luminal A, luminal B (HER2 negative and HER2 positive), HER2 positive (nonluminal), and triple negative;
- (ii) detect the association between intrinsic subtypes, clinical-pathological features, and outcome;
- (iii) investigate the difference between prognostic impacts of luminal A and B subtypes with the same tumor stage.

2. Patients and Methods

2.1. Description of the Patients' Cohort. All patients were resident in a province in the northern-east area of Italy. Inclusion criteria were (i) diagnosis of BC at least 15 years before the censoring date of the study (December 31 2008), (ii) invasive BC of stage I–III, (iii) age at diagnosis 55 years or younger, and (iv) availability of formalin-fixed and paraffin-embedded (FFPE) tissues. Cases with a second primary breast cancer or other malignancies were excluded from the study. From 380 women initially enrolled, 75 patients with *in situ* BC were excluded. Accordingly, 305 patients represented the final cohort for the study, of these 154 (50.4%) presented with lymph node involvement (LN+) at diagnosis. FFPE tissues of the primary tumor obtained by surgical treatment were used. Clinical information was obtained from medical records. Tumors were reviewed and histologically classified according to the World Health Organization (WHO 2003) [16], graded using Elston and Ellis grading system [17] and grouped into stages according to TNM classification [18]. The patients' cohort was followed for a maximum of 25 years through the local Cancer Registry from diagnosis of BC to death or until censoring date. This study was approved by the Ethical Committee of the University of Trieste.

Fifteen patients (5%) were lost at follow-up during the period of observation because of emigration. The mean age at diagnosis was 47 years (range 26–55). No significant differences in age at diagnosis were observed between the LN– (46.8 y, range 32–55 y) and LN+ (47.0 y, range 26–55 y) groups, but the frequency of patients under 35 years was higher in LN+.

Patients were treated with mastectomy or breast-conserving surgery. All patients submitted to conserving

surgery were treated with radiotherapy. All LN+ patients were treated with adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, and fluorouracil) or EC/ECF (epirubicin, cyclophosphamide, and fluorouracil) regimens according to standard protocols. ER-positive patients, both LN– and LN+, were submitted to hormone therapy with tamoxifen. No specific treatment with trastuzumab was performed in HER2 positive patients, because this therapy was not available at the time of diagnosis.

The median follow-up time was 16 years (range 0–25). In detail it was 18 years (range 0–25) for the LN– group and 9 years (range 0–24) for the LN+ group ($P = 0.000$). In the LN– group 49 women (33%) recurred, while in the LN+ group 98 patients (69%) did so. For 4 LN– patients (3%) and 11 LN+ ones (7%) no information about recurrences was given. All clinical and pathological characteristics are reported in Table 1.

2.2. Tissue Microarray. Each patient's haematoxylin and eosin (H&E) slides were reviewed by an expert pathologist (R. Barbazza), who marked the representative tumor areas to be analyzed. Tissue microarrays (TMAs) were constructed by the use of the FFPE tissues of the entire cohort using the Galileo TMA CK3500 (Integrated Systems Engineering, Milano, Italy), as previously described [19]. Multiple tissue cores were sampled when the tumor presented with histological heterogeneous regions. One section from each TMA block was stained with H&E to confirm the presence of carcinoma.

2.3. Immunohistochemical Staining. IHC staining was performed following the standard procedures [20], according to the manufacturers' instructions for each MAB used. Immunostaining was performed manually with the Vectastain Universal Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) for ER, PR, CK8, CK5/6, and vimentin. Ready-to-use antibodies for ER (CONFIRM anti-Estrogen Receptor clone SP1; Ventana Medical System, Tucson, AZ, USA), PR (CONFIRM anti-Progesterone Receptor clone 1E2; Ventana), vimentin (CONFIRM anti-Vimentin clone V9; Ventana), and CK5/6 (clone D5&16B4; diluted 1:100 Aczon Biotech, Monte San Pietro, Bologna, Italy) were applied for 60 minutes after 20-minute antigen retrieval in 0.1 M pH 8 Tris-Borate 1 mM EDTA at high temperature, in water bath. CK8 antibody (clone M20; Abcam, Cambridge, UK) was used at 1:250 dilution with 60-minute incubation, after 20-minute antigen retrieval in 10 mM pH6 Citrate Buffer at high temperature in water bath. For visualization, the DAB Substrate kit for Peroxidase (Vector Laboratories, Burlingame, CA, USA) was used.

Immunostaining for Ki67 (clone MIB-1; 1:200 dilution, DakoDenmark A/S, Glostrup, Denmark) and HER2 (clone CB11; 1:300 dilution Thermo Scientific, Astmoor Runcorn, Cheshire, UK) was performed in Lab Vision Autostainer 480S (Thermo Scientific) with the UltraVision LP Large Volume Detection System HRP Polymer (Lab Vision Corporation, Thermo Scientific) according to manufacturer's instructions. HER2 gene amplification in case of equivocal staining (2+)

TABLE 1: Clinical-pathological parameters and immunohistochemistry results of the BC cohort ($N = 305$) and with respect to lymph node involvement.

Features	Entire cohort (305) n (%)	LN- (151) n (%)	LN+ (154) n (%)	P
Mean age, years	46.9	46.8	47.0	0.2
(range)	(26–55)	(32–55)	(26–55)	
Age, years				0.004*
≤35	21 (7)	4 (3)	17 (11)	
>35	284 (93)	147 (97)	137 (89)	
Histology				0.001*
Ductal	250 (83)	117 (77)	136 (88)	
Lobular	28 (9)	13 (9)	15 (10)	
Medullary	6 (2)	6 (4)	0	
Mucinous	7 (2)	4 (3)	3 (2)	
Tubular	12 (4)	11 (7)	0	
Grade				0.000*
1	39 (13)	34 (22)	5 (3)	
2	145 (47)	86 (57)	59 (38)	
3	121 (40)	31 (21)	90 (59)	
Tumor size, cm				0.000*
≤2	181 (60)	109 (72)	72 (48)	
2–5	106 (35)	39 (26)	67 (44)	
≥5	15 (5)	3 (2)	12 (8)	
Missing	3	0	3	
Lymph nodes				
1–3 lymph nodes	97 (63)	0	97 (63)	
≥4 lymph nodes	56 (37)	0	56 (37)	
Missing	1	0	1	
Stage				
I	107 (35)	107 (71)	0	
II	125 (41)	42 (28)	83 (54)	
III	72 (24)	2 (1)	70 (46)	
Missing	1	0	1	
Type of surgery				0.001*
Mastectomy	221	88	133	
Breast conservation	84	63	21	
Recurrence				0.000*
No	143 (49)	98 (67)	45 (31)	
Yes	147 (51)	49 (33)	98 (69)	
Missing	15	4	11	
BC specific death	128 (42)	39 (26)	89 (58)	0.000*
Living	143 (47)	99 (65)	44 (28)	
Other cause death	16 (5)	7 (5)	9 (6)	
Lost at FU	18 (6)	6 (4)	12 (8)	
ER				0.08
Negative	63 (21)	25 (17)	38 (25)	
Positive	242 (79)	126 (83)	116 (75)	
PR				0.001*
Negative	81 (27)	27 (18)	54 (35)	
Positive	224 (73)	124 (82)	100 (65)	
HER2				0.000*
Negative	244 (80)	140 (93)	104 (67)	
Positive	61 (20)	11 (7)	50 (33)	

TABLE I: Continued.

Features	Entire cohort (305) n (%)	LN- (151) n (%)	LN+ (154) n (%)	P
Ki67				
<14%	156 (51)	104 (69)	52 (34)	0.000*
≥14%	149 (49)	47 (31)	102 (66)	
CK8				
Negative	29 (10)	11 (7)	18 (12)	0.3
Positive	276 (90)	140 (93)	136 (88)	
CK5/6				
Negative	235 (77)	109 (72)	126 (82)	0.04*
Positive	70 (23)	42 (28)	28 (18)	
Vimentin				
Negative	196 (64)	106 (70)	90 (58)	0.03*
Positive	109 (36)	45 (30)	64 (42)	
AR				
Negative	80 (37)	29 (30)	51 (43)	0.04*
Positive	136 (63)	69 (70)	67 (57)	

ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor-2, CK8: cytokeratin 8, CK5/6: cytokeratin 5/6, AR: androgen receptor. *Statistically significant data.

was assessed by SISH assays using the *ultra View* SISH DNP Detection Kit (Ventana) in Benchmark XT automated slide stainer instrument, as previously described [21].

IHC for androgen receptor (AR) was performed with mouse monoclonal antibody (AR441, DakoDenmark A/S, Glostrup, Denmark) as previously described [22].

Positive and negative control slides were used in each IHC assay.

2.4. Evaluation of Immunohistochemistry and Definition of Intrinsic Subtypes. Immunostaining was quantitatively evaluated by two different observers in a blinded fashion (DP, RB) using light microscopy and counting the positive cells across three high power fields (HPF at 40x magnification), each containing about one hundred cells. Tumors were considered as positive for ER and PR if more than 10% of tumor nuclei were stained independently of staining intensity [10, 23], because at the time of diagnosis this was the cutoff used to submit patients to Tamoxifen treatment. This is a deviation from the St. Gallen consensus and ASCO/CAP guidelines, which defined those cases presenting with more than 1% of tumor cells independently of staining intensity as hormonal receptor positive [7, 24]. The cutoff for CK8 and CK5/6 positivity was 10% of cells as well. Tumors were considered as positive for vimentin and AR when more than 1% of tumor cells were stained [22, 25].

HER2 overexpression was scored according to ASCO guideline [26]. Our patients had a diagnosis of BC between 1983 and 1993 and no specific treatment with trastuzumab was performed in those years. Since we had no information about the scoring of HER2 at the time of diagnosis, we adopted the current method. For evaluation of Ki67 immunostaining, the positively stained cancer cells were counted manually across three high power fields (HPF). The mean value was used for Ki67 score. Ki67 threshold of 14% of nuclear staining of cancer cells was used to discriminate low proliferation

index (<14%) and high proliferation index (≥14%) [5, 7]. The tumors were then classified into the four main intrinsic subtypes according to the staining profile of the antigen markers: ER, PR, HER2, and Ki67 [5, 7, 11, 27]. CK8, CK5/6, vimentin, and AR were investigated in the entire case study. In detail, cases that were ER positive and/or PR positive, HER2 negative, and low Ki67 were classified as luminal A; cases that were either (i) ER positive and/or PR positive, HER2 negative, and high Ki67 (luminal B HER2 negative) or (ii) ER positive and/or PR positive, HER2 positive (luminal B HER2 positive) were classified as Luminal B; tumors ER negative, PR negative, and HER2 positive were defined as HER2 positive; cases ER negative, PR negative, and HER2 negative, were classified as triple negative (TN), a surrogate for subtype [6]. If the tumors exhibited markers staining that did not meet the abovementioned panel criteria, they were defined as “unclassified.”

2.5. Statistical Analysis. Associations between clinical-pathological data, lymph node involvement, and intrinsic subtypes were tested for significance using the Chi-square test for categorical variables. For continuous variables the parametric Student's *t*-test, the one-way ANOVA test, or the Kruskal-Wallis test was used. BC specific survival was defined as the time from surgery to breast cancer specific death or end of follow-up, whichever came first. To estimate the joint effects of the analyzed covariates on patients' survival, the data were analyzed by fitting the Cox proportional hazard regression model. Cox proportional hazard analysis included pathological variables (age at diagnosis, histological type, tumor size, lymph nodes status, and tumor grade) and intrinsic subtypes as covariates. The log-rank test was used to check the dependence of patients' survival on single variables or on combinations of variables. All *P* values are two sided with values <0.05 regarded as statistically significant. *P* values between 0.05 and 0.07 were considered as “borderline.”




FIGURE 1: Kaplan-Meier survival curves with respect to molecular classes in (a) the cohort of BC patients ($N = 304$, 128 BC specific deaths), (b) lymph node negative tumors ($N = 150$, 39 BC specific deaths), and (c) classes in lymph node positive tumors ($N = 154$, 89 BC specific deaths).

Statistical analyses were performed with the Stata/SE 12 package (Stata, College Station, TX, USA).

3. Results

3.1. Survival according to Intrinsic Subtypes. The BC specific survival curves per intrinsic subtypes for the entire cohort are shown in Figure 1. A significantly better BC specific survival was recorded for luminal A tumors and a worse outcome was observed for HER2 positive nonluminal subtype ($P = 0.0003$). In detail, significant differences were found between luminal A and luminal B ($P = 0.009$), luminal A and HER2 positive (nonluminal) ($P = 0.0003$), luminal A and TN ($P = 0.01$), and luminal B and HER2 positive nonluminal ($P = 0.04$). Therefore no significant differences between HER2 positive nonluminal and TN ($P = 0.3$), and luminal B and TN ($P = 0.5$) were detected.

Considering luminal A and B together, PR positive tumors showed a significantly better outcome in comparison with negative ones ($P = 0.02$), as shown in Figure 2. Vimentin-positive luminal tumors had shorter survival compared to negative ones ($P = 0.03$) (Figure 3). HER2 ($P = 0.5$) and CK5/6 ($P = 0.9$) expression did not seem to influence BC specific survival among luminal tumors. Moreover, luminal A tumors, but not luminal B, with AR-positive expression showed significant longer survival with respect to negative ones ($P = 0.01$), as shown in Figure 4.




FIGURE 2: Kaplan-Meier survival curves according to PR expression in luminal tumors ($N = 240$, 93 BC specific deaths).

Cox multivariate analysis run for pathological variables and for the molecular subtypes revealed that histological type, tumor grade, lymph node involvement, and luminal tumors (A and B) showed an independent influence on BC specific survival, as reported in Table 2.




FIGURE 3: Kaplan-Meier survival curves according to vimentin expression in luminal tumors ($N = 240$, 93 BC specific deaths).




FIGURE 4: Kaplan-Meier survival curves according to AR in luminal A tumors ($N = 92$, 32 BC specific deaths).

TABLE 2: Cox multivariate regression analysis for breast cancer survival in the entire cohort ($N = 302$).

Risk factors	Hazard ratio	95% CI*	P
Age at diagnosis	1.0	0.9-1.0	0.4
Histologic type	0.8	0.6-1.0	0.04*
Grade	1.4	1.0-1.9	0.05
Tumor size	1.2	0.9-1.7	0.2
Lymph node	2.4	1.5-3.7	0.000*
Luminal A	0.2	0.1-0.9	0.04*
Luminal B	0.2	0.1-0.8	0.03*
HER2 positive nonluminal	0.3	0.1-1.4	0.1
Triple negative	0.4	1.0-1.6	0.2

*Statistically significant data.

By comparing luminal patients who had BC specific death within 10 years (68 out of 93) with those who died from BC after 10 years (25 out of 93), tumors with higher Ki67

($P = 0.02$) and positive to vimentin ($P = 0.02$) tend to cause more frequently “late” BC specific death.

3.2. Clinical Pathological Features of Intrinsic Subtypes. Luminal A was the most frequent molecular subtype with 140 patients (46%), followed by luminal B with 102 women (34%), 38 TN (12%), and 24 HER2 positive (nonluminal) (8%). One case failed to be classified in one of the molecular subtypes, because it exhibited staining for PR, CK8, and high Ki67, but not for ER, HER2, and CK5/6.

Clinical and pathological details stratified per intrinsic subtypes are shown in Table 3.

Significant associations between intrinsic subtypes and age at diagnosis (cutoff 35 years) ($P = 0.03$), histological type ($P = 0.001$), tumor grade ($P = 0.000$), lymph node involvement ($P = 0.000$), tumor stage ($P = 0.000$), and presence of later recurrences ($P = 0.006$) were found. Patients under 35 years at diagnosis more frequently fell into luminal B and HER2 positive (nonluminal) subtypes. Tumor size distribution did not show any difference in the intrinsic subtypes, but it was significantly higher in LN+ group ($P = 0.000$).

An important association between molecular classification and LN involvement was detected ($P = 0.000$). Most luminal A tumors were of stage I at diagnosis, while most luminal B tumors were of stage II and nearly half of HER2 positive (nonluminal) of stage III. TN tumors were equally distributed in the three stages. In the entire case study, luminal A subtype showed the lowest percentage of recurrences, while more than 75% of HER2 positive nonluminal tumors relapsed. Luminal B and TN patients showed a similar intermediate percentage of recurrences.

Vimentin prevailed in triple negative subgroup (75% of positive tumors) as compared to other classes ($P = 0.000$).

AR was evaluated in 216 tumors (tissue cores of 89 patients were not analyzable on TMAs), of which 136 were positive, as reported in Table 1. AR-positive staining was significantly associated with LN- tumors ($P = 0.04$), low-grade tumors ($P = 0.001$), and tumor stage I-II ($P = 0.04$). All medullary tumors were AR negative, whereas 75% of mucinous and 88% of tubular carcinomas were AR positive ($P = 0.02$). No significant association between AR positivity and tumor size was detected; however, the log-rank test revealed a significantly better outcome for patients showing positive AR expression, in comparison to negative ones, on the whole cohort ($P = 0.03$). Moreover, AR positivity was significantly associated with ER-positive ($P = 0.000$) and PR-positive ($P = 0.000$) tumors.

When we analyzed LN- and LN+ groups separately, we observed similar frequency of recurrences for luminal subtypes: 33% and 26% of recurrences in luminal A and luminal B in LN-; 64% and 67% for luminal A and B in LN+, respectively ($P = 0.6$ and $P = 0.8$). The result was also confirmed for cancer specific deaths: frequencies were comparable in luminal A and B subgroups when divided per lymph node involvement ($P = 0.9$ for both). Survival rates of luminal A and B patients were 0.75 at 25 years for both in lymph LN- and in LN+, they were 0.42 for luminal A and 0.34 for luminal B (at 25 years).

TABLE 3: General clinical-pathological parameters and immunohistochemistry results of breast tumors according to molecular classification (N = 304).

Features	Luminal A (140) n (%)	Luminal B (102) n (%)	HER2 (24) n (%)	Triple negative (38) n (%)	P
Age at diagnosis, years (range)	47.4 (30–55)	46.6 (30–55)	45.9 (28–55)	46.5 (26–55)	0.7
Age, years					
≤35	4 (3)	10 (10)	4 (17)	3 (8)	0.04*
>35	136 (97)	92 (90)	20 (83)	35 (92)	
Histology					
Ductal	110 (79)	89 (87)	23 (96)	30 (79)	0.002*
Lobular	16 (11)	10 (10)	1 (4)	1 (3)	
Medullary	0	0	0	6 (16)	
Mucinous	3 (2)	3 (3)	0	1 (3)	
Tubular	11 (8)	0	0	0	
Grade					
1	34 (25)	5 (4)	0	0	0.000*
2	77 (55)	49 (48)	9 (37)	9 (24)	
3	29 (20)	48 (48)	15 (63)	297 (76)	
Tumor size, cm					
≤2	95 (68)	50 (49)	12 (50)	23 (62)	0.1
2–5	39 (28)	44 (43)	11 (46)	12 (32)	
≥5	5 (4)	7 (7)	1 (4)	2 (5)	
Missing	1	1	0	1	
Lymph node involvement					
No	98 (70)	28 (27)	5 (21)	19 (50)	0.000*
Yes	42 (30)	74 (73)	19 (79)	19 (50)	
Lymph nodes					
1–3	28 (67)	51 (69)	10 (53)	8 (44)	0.1
≥4	14 (33)	23 (31)	9 (47)	10 (56)	
Missing	0	0	0	1	
Stage					
I	71 (51)	17 (16)	4 (16)	14 (38)	0.000*
II	48 (34)	55 (54)	9 (38)	13 (35)	
III	21 (15)	30 (30)	11 (46)	10 (27)	
Missing	0	0	0	1	
Recurrence					
No	78 (58)	43 (45)	5 (23)	16 (42)	0.02*
Yes	56 (42)	53 (55)	17 (77)	21 (55)	
Missing	6	6	2	1	
Status					
BC specific death	45 (32)	48 (47)	14 (58)	21 (55)	
ER					
Negative	0	0	24 (100)	38 (100)	
Positive	140 (100)	102 (100)	0	0	
PR					
Negative	6 (4)	13 (13)	24 (100)	38 (100)	
Positive	134 (96)	89 (87)	0	0	
HER2					
Negative	140 (100)	65 (64)	0	38 (100)	
Positive	0	37 (36)	24 (100)	0	

TABLE 3: Continued.

Features	Luminal A (140) <i>n</i> (%)	Luminal B (102) <i>n</i> (%)	HER2 (24) <i>n</i> (%)	Triple negative (38) <i>n</i> (%)	<i>P</i>
Ki67					
<14%	140 (100)	6 (6)	4 (17)	6 (16)	
≥14%	0	96 (94)	20 (83)	32 (84)	
CK8					
Negative	0	0	5 (21)	24 (63)	
Positive	140 (100)	102 (100)	19 (79)	14 (37)	
CK5/6					
Negative	125 (89)	89 (87)	19 (79)	2 (5)	
Positive	15 (11)	13 (13)	5 (21)	36 (95)	
Vimentin					
Negative	107 (76)	65 (64)	14 (58)	10 (26)	0.000*
Positive	33 (24)	37 (36)	10 (42)	28 (74)	
AR					
Negative	19 (21)	20 (26)	14 (70)	26 (100)	0.000*
Positive	73 (79)	57 (74)	6 (30)	0	

ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor, CK8: cytokeratin 8, CK5/6: cytokeratin 5/6, AR: androgen receptor. *Statistically significant data.

TABLE 4: Metastasis sites and local recurrence in accordance with BC molecular subtypes.

Intrinsic subtypes (<i>n</i>)	Local <i>n</i> (%)	Bone <i>n</i> (%)	Liver <i>n</i> (%)	Lung and pleura <i>n</i> (%)	Brain <i>n</i> (%)	Endocrine ^a <i>n</i> (%)	Distant LN ^b <i>n</i> (%)	Other ^c <i>n</i> (%)
Luminal A (140)	22 (16)	23 (16)	28 (21)	25 (18)	2 (1)	4 (3)	4 (3)	5 (4)
Luminal B (102)	13 (13)	29 (28)	27 (26)	20 (20)	8 (8)	4 (4)	2 (2)	6 (6)
HER2 positive (24)	7 (29)	3 (12)	7 (29)	6 (25)	4 (17)	1 (4)	1 (4)	1 (4)
TN (38)	5 (13)	12 (32)	13 (34)	14 (37)	4 (11)	1 (3)	1 (3)	1 (3)

^aEndocrine sites include thyroid, ovary, and kidney. ^bDistant lymph nodes are considered the nodes that do not belong to the axilla, including the supraclavicular lymph nodes. ^cOther sites comprise peritoneum and pericardium.

3.3. Pattern of Local and Distant Metastases. The pattern of metastatic sites was reported in Table 4. Organ distribution of metastasis among intrinsic subtypes was almost similar, but for bone and brain. HER2 positive (nonluminal) type exhibited a lower rate (12%) of bone metastasis in comparison to other subtypes ($P = 0.03$). In particular, for bone involvement significant differences were found between HER2 positive (nonluminal) and luminal B ($P = 0.01$) and TN ($P = 0.04$). A higher rate of brain metastases was found in both HER2 positive (nonluminal) (17%) and TN (11%) ($P = 0.03$). In detail, a significant difference for brain metastases was observed between HER2 positive (nonluminal) and luminal A ($P = 0.02$) and TN and luminal A ($P = 0.04$).

4. Discussion

Current BC clinical management is based on the assessment of traditional clinical and pathological factors and some molecular markers, such as ER, PR, HER2, and Ki67. More recently, the 2011 St Gallen International Breast Cancer Conference [7] suggested using immunohistochemistry for molecular subtyping [5, 7, 8, 14] with the analysis of ER, PR, HER2, and Ki67 to subdivide patients into luminal A and B, HER2 positive nonluminal, and triple negative.

In this study we investigated the prognostic role of BC molecular classification in a cohort of 305 BC patients aged 55 years or younger at diagnosis, to obtain a long follow-up (mean follow-up: 14 years). To this purpose we used the panel of four biomarkers for molecular subgrouping by IHC, ER, PR, HER2, Ki67, [5, 6, 28, 29], plus CK8, CK5/6 (to confirm the luminal and basal-like types), vimentin, and AR as additional markers.

The distribution of intrinsic subtypes obtained by IHC in our patients' cohort was similar to other previous studies [11, 27, 30]: luminal tumors were the most represented subtype with 80% of cases, followed by TN cancers (12%) and HER2 positive nonluminal (8%). In agreement with other studies, a significant association between clinical-pathological features and molecular subtypes was observed [3, 6, 8, 31]. In particular, most low-grade tumors that displayed features of luminal A, conversely poorly differentiated were mainly luminal B and HER2 positive nonluminal subtypes ($P = 0.000$). In TN subtype the rate of G3 tumors was significantly higher, as already reported [6, 32]. Regarding BC histology, pure tubular and mucinous types, related to a favorable prognosis [16], were luminal tumors, as well as lobular ones. HER2 positive nonluminal and TN molecular classes tumors were mostly of the ductal histological type, as already reported [29, 33].

Medullary carcinomas, whose histological type is rare, were classified as triple negative tumors [29, 31].

Regarding ER-positive tumors, luminal A type was mainly represented in LN-, while luminal B was more common in the LN+ group, and this is the main clinical difference between the two groups. Luminal B and HER2 positive nonluminal frequently presented at diagnosis with lymph node involvement, in agreement with Wiechmann et al. [30]. Conversely, TN tumors were equally distributed between LN- and LN+ groups, showing that its prognosis is mainly related to their intrinsic biological behavior [34]. Triple negative, as well as HER2 positive nonluminal, subtypes presented with higher rate of brain metastasis in comparison with luminal A tumors, in agreement with other reports [11, 12, 34].

A few luminal A tumors exhibited cancer specific death, while the HER2 positive nonluminal subtype presented with the highest rate of relapses, as already reported [11]. Luminal B and TN showed a similar intermediate frequency of recurrences, also reflected by specific survival (Figure 1(a)). However, if we consider luminal A and B by lymph node involvement, they exhibited in the two groups similar frequencies of recurrences. These data are also confirmed by BC specific survival as shown in Figures 1(b) and 1(c). This finding is related to the fact that the cutoffs to define luminal A and luminal B cancer are arbitrarily set [14], and by IHC they differ for the rate of Ki67 and HER2 overexpression, both characteristic of higher aggressiveness. Our results point out that the recurrence rate and cancer specific deaths are highly dependent on the status of axillary lymph nodes rather than on splitting between luminal A and B subtypes. In agreement with us, recent studies have called into question the very existence of this subclassification and have suggested that ER-positive cancers form a continuum rather than segregate into distinct subtypes [14]. However, we recognize as a possible limitation that in this study no luminal B HER 2 positive subclassification has been performed, because of the limited number of cases.

In our cohort, luminal B tumors were often negative to PR ($P = 0.03$), but positive to vimentin expression ($P = 0.003$) with respect to luminal A. Other authors have already reported on vimentin expression in luminal epithelium of the breast and on its positive correlation with ER in BC tumors [25, 35].

Furthermore, vimentin expression and higher Ki67 were significantly associated with worse survival in the subgroup of luminal patients who died from BC after 10 years. This suggests that vimentin and Ki67 could represent long-term unfavorable prognostic markers in ER-positive tumors. We also observed that most ER-positive tumors were positive to AR, which seem to be a marker of good prognosis, as already reported [22], especially in early stages of luminal tumors. Of note in the period of diagnosis of our cohort of patients, LN- patients were not treated with cytotoxic chemotherapy, according to regimens of those years.

To our knowledge this is the first study investigating BC specific survival associated with intrinsic subtypes in a population with up to 25 years of follow-up. As expected, we observed that BC specific survival analysis identified two well

separated groups of tumors: ER-positive and ER-negative. ER-positive LN negative cancers have the best outcome, and ER-positive LN positive cases showed an intermediate overall survival, while TN and HER2 positive nonluminal types showed the shortest survival, as already reported [2, 3, 11, 14, 33]. HER2 positive nonluminal and TN subtypes displayed a very aggressive outcome with early BC specific death within 5 and 10 years, respectively. However we recognize that a possible limitation of the study is the low number of patients in the HER2 positive non luminal (24) and TN (38) subtypes.

Cox proportional hazard model confirmed an independent and favorable influence on BC survival for luminal tumors (ER-positive), together with the pathological variables, histological type, tumor grade, and lymph node involvement.

Taken together, our results stress that, in our experience, luminal A and luminal B belong to a unique clinical group of ER-positive tumors, and their clinical differences are mainly related to a different tumor stage at diagnosis. We also observed that the most important predictor of prognosis ER-positive tumors was still the lymph node involvement, which is still reported as one of the most relevant prognostic factors [36].

Although patients with luminal tumors showed significantly longer BC survival, they frequently undergo over 10-year long-term BC deaths [11]. In our case study 10% of luminal BC patients died from BC after 10 years of follow-up. It is possible to hypothesize that ER-positive tumors with high Ki67 and vimentin positivity harbor some specific biological properties that slow down progression for a very long time and may postpone BC specific death even for 20 years.

Therefore we strongly believe that monitoring and follow-up program should be different according to cancer subtypes, and, in case of luminal tumors, prolonged controls are recommended because of possible relapses.

5. Conclusion

Luminal tumors (ER positive) showed longer survival and better prognosis with respect to ER-negative ones, as it is widely accepted. In addition, AR resulted in a significant prognostic marker among luminal A patients. From our long-term survival study ER-positive tumors are confirmed to be a single clinical group, diagnosed in different periods of cancer progression. The prognosis is good for LN- ER-positive patients independently of any further molecular class and very severe for LN+. In this group, general survival after 20 years is very similar to HER2 positive nonluminal tumors after 5 years and to TN after 10 years.

Finally, together with Ki67 the use of PR and vimentin as prognostic markers could help to better stratify patients with ER-positive tumors with respect to clinical outcome.

Conflict of Interests

The authors declare no conflict of interests.



Acknowledgments

The authors would like to thank Dr. Valentina Melita for the language revision of the paper. The authors are also grateful to Dr. Maria Malagoli for providing the oncological therapy regimens. This study was partially supported by the MIUR PRIN 2008, Protocol no. 2008YFRLC8_002.

References

- [1] P. E. Colombo, F. Milanezi, B. Weigelt, and J. S. Reis-Filho, "Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction," *Breast Cancer Research*, vol. 13, p. 212, 2011.
- [2] C. M. Perou, T. Sørile, M. B. Eisen et al., "Molecular portraits of human breast tumours," *Nature*, vol. 406, no. 6797, pp. 747–752, 2000.
- [3] T. Sørlie, C. M. Perou, R. Tibshirani et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 19, pp. 10869–10874, 2001.
- [4] B. Weigelt, F. L. Baehner, and J. S. Reis-Filho, "The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade," *Journal of Pathology*, vol. 220, no. 2, pp. 263–280, 2010.
- [5] M. C. U. Cheang, S. K. Chia, D. Voduc et al., "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer," *Journal of the National Cancer Institute*, vol. 101, no. 10, pp. 736–750, 2009.
- [6] P. Tang, K. A. Skinner, and D. G. Hicks, "Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?" *Diagnostic Molecular Pathology*, vol. 18, no. 3, pp. 125–132, 2009.
- [7] A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann, and H.-J. Senn, "Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011," *Annals of Oncology*, vol. 22, no. 8, pp. 1736–1747, 2011.
- [8] A. M. Gruver, B. P. Portier, and R. R. Tubbs, "Molecular pathology of breast cancer the journey from traditional practice toward embracing the complexity of a molecular classification," *Archives of Pathology and Laboratory Medicine*, vol. 135, no. 5, pp. 544–557, 2011.
- [9] S. Guiu, S. Michiels, F. Andre et al., "Molecular subclasses of breast cancer: how do we define them? The IMPAKT, 2012 Working Group Statement," *Annals of Oncology*, vol. 23, pp. 2997–3006, 2012.
- [10] B. M. Müller, R. Kronenwett, G. Hennig et al., "Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue—a new option for predictive biomarker assessment in breast cancer," *Diagnostic Molecular Pathology*, vol. 20, no. 1, pp. 1–10, 2011.
- [11] S. Park, J. S. Koo, M. S. Kim et al., "Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry," *Breast*, vol. 21, no. 1, pp. 50–57, 2012.
- [12] E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis, "Basal-like breast cancer: a critical review," *Journal of Clinical Oncology*, vol. 26, no. 15, pp. 2568–2581, 2008.
- [13] M. M. Shao, S. K. Chan, A. M. Yu et al., "Keratin expression in breast cancers," *Virchows Archiv*, vol. 461, no. 3, pp. 313–322, 2012.
- [14] F. C. Geyer, D. N. Rodrigues, B. Weigelt, and J. S. Reis-Filho, "Molecular classification of estrogen receptor-positive/luminal breast cancers," *Advances in Anatomic Pathology*, vol. 19, no. 1, pp. 39–53, 2012.
- [15] E. A. Rakha and I. O. Ellis, "Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics," *Advances in Anatomic Pathology*, vol. 18, no. 4, pp. 255–267, 2011.
- [16] I. O. Ellis, S. J. Schnitt, X. Sastre-Garau et al., *World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs*, IARC Press, Lyon, France, 2003, Edited by Tavassoli F. A., Devilee P.
- [17] C. W. Elston and I. O. Ellis, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up," *Histopathology*, vol. 19, no. 5, pp. 403–410, 1991.
- [18] S. B. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene, and A. Trotti, *AJCC Cancer Staging Manual*, 7th Edition edition, 2010.
- [19] V. Faoro and A. Sapino, "Tissue Microarray," in *Guidelines For Molecular Analysis in Archive Tissues*, G. Stanta, Ed., pp. 23–26, Springer, Berlin, Germany, 2011.
- [20] N. S. Goldstein, S. M. Hewitt, C. R. Taylor et al., "Recommendations for improved standardization of immunohistochemistry," *Applied Immunohistochemistry and Molecular Morphology*, vol. 15, no. 2, pp. 124–133, 2007.
- [21] M. T. Ramieri, R. Murari, C. Botti, E. Pica, G. Zotti, and P. L. Alo, "Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma," *Anticancer Research*, vol. 30, no. 4, pp. 1287–1292, 2010.
- [22] I. Castellano, E. Allia, V. Accortanzo et al., "Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers," *Breast Cancer Research and Treatment*, vol. 124, no. 3, pp. 607–617, 2010.
- [23] X.-R. Li, M. Liu, Y.-J. Zhang et al., "Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer," *Medical Oncology*, vol. 28, no. 1, pp. S31–S38, 2011.
- [24] M. E. H. Hammond, D. F. Hayes, A. C. Wolff, P. B. Mangu, and S. Temin, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer," *Journal of Oncology Practice*, vol. 6, no. 4, pp. 195–197, 2010.
- [25] R. U. Kusinska, R. Kordek, E. Pluciennik, A. K. Bednarek, J. H. Piekarski, and P. Potemski, "Does vimentin help to delineate the so-called 'basal type breast cancer'?" *Journal of Experimental and Clinical Cancer Research*, vol. 28, no. 1, article 118, 2009.
- [26] A. C. Wolff, M. E. H. Hammond, J. N. Schwartz et al., "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer," *Journal of Clinical Oncology*, vol. 25, no. 1, pp. 118–145, 2007.
- [27] S. Dawood, R. Hu, M. D. Homes et al., "Defining breast cancer prognosis based on molecular phenotypes: results from a large

- cohort study," *Breast Cancer Research and Treatment*, vol. 126, no. 1, pp. 185–192, 2011.
- [28] E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis, "Combinatorial biomarker expression in breast cancer," *Breast Cancer Research and Treatment*, vol. 120, no. 2, pp. 293–308, 2010.
- [29] M. D. Valentin, S. D. da Silva, M. Privat, M. Alaoui-Jamali, and Y.-J. Bignon, "Molecular insights on basal-like breast cancer," *Breast Cancer Research and Treatment*, pp. 1–10, 2012.
- [30] L. Wiechmann, M. Sampson, M. Stempel et al., "Presenting features of breast cancer differ by molecular subtype," *Annals of Surgical Oncology*, vol. 16, no. 10, pp. 2705–2710, 2009.
- [31] B. Weigelt, F. C. Geyer, and J. S. Reis-Filho, "Histological types of breast cancer: How special are they?" *Molecular Oncology*, vol. 4, no. 3, pp. 192–208, 2010.
- [32] C. A. Livasy, G. Karaca, R. Nanda et al., "Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma," *Modern Pathology*, vol. 19, no. 2, pp. 264–271, 2006.
- [33] A. García Fernández, N. Giménez, M. Fraile et al., "Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010," *Breast*, vol. 21, pp. 366–373, 2012.
- [34] S. J. Crabb, M. C. U. Cheang, S. Leung et al., "Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer," *Clinical Breast Cancer*, vol. 8, no. 3, pp. 249–256, 2008.
- [35] M. Heatley, C. Whiteside, P. Maxwell, and P. Toner, "Vimentin expression in benign and malignant breast epithelium," *Journal of Clinical Pathology*, vol. 46, no. 5, pp. 441–445, 1993.
- [36] C. Tausch, S. Taucher, P. Dubsy et al., "Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG)," *Annals of Surgical Oncology*, vol. 19, pp. 1808–1817, 2012.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

